𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma

✍ Scribed by Jorge A. Garcia; Tarek Mekhail; Paul Elson; Laura Wood; Ronald M. Bukowski; Robert Dreicer; Brian I. Rini

Book ID
110923491
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
136 KB
Volume
109
Category
Article
ISSN
1464-4096

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of subcutaneously adminis
Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma
✍ Edward Wos; Thomas Olencki; Laurie Tuason; G. Thomas Budd; David Peereboom; Kate 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 465 KB 👁 2 views

## BACKGROUND. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that is involved in the differentiation and proliferation of various hematopoietic precursors. It also has been reported to enhance the antitumor activity of various mature effector cells. Previous reports have

Granulocyte-macrophage–colony stimulatin
Granulocyte-macrophage–colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma : Results of two Phase II clinical trials
✍ Christopher W. Ryan; Nicholas J. Vogelzang; Mary C. Dumas; Timothy Kuzel; Walter 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

The aim of this study was to determine the response rates and toxicity of two regimens containing granulocyte-macrophage-colony stimulating factor (GM-CSF) in combination with interleukin-2 (IL-2) in the treatment of patients with metastatic renal cell carcinoma. ## METHODS. Therapy given in the f

A Phase II trial of intravenous gemcitab
A Phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma
✍ Christopher W. Ryan; Nicholas J. Vogelzang; Walter M. Stadler 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

## Abstract ## BACKGROUND The objective of this study was to determine the response rate and toxicity of gemcitabine and continuous‐infusion 5‐fluorouracil (5‐FU) in combination with subcutaneous interleukin‐2 (IL2) and interferon‐α (IFNA) in patients with metastatic renal cell carcinoma. ## METH